- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 236850, 8 pages
Exploring Different Virtual Screening Strategies for Acetylcholinesterase Inhibitors
Department of Pharmaceutical Sciences, Birla Institute of Technology, Mesra, Ranchi 835215, India
Received 11 April 2013; Revised 12 August 2013; Accepted 4 September 2013
Academic Editor: J. Guy Guillemette
Copyright © 2013 Nibha Mishra and Arijit Basu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- E. R. Kandel, J. H. Schwartz, and T. M. Jessell, Principles of Neural Science., E. R. Kandel, Ed., Appleton & Lange, Norwalk, Conn, USA, 1991.
- S. Moghul and D. Wilkinson, “Use of acetylcholinesterase inhibitors in Alzheimer's disease,” Expert Review of Neurotherapeutics, vol. 1, no. 1, pp. 61–69, 2001.
- W. L. M. Alward, “Medical management of glaucoma,” New England Journal of Medicine, vol. 339, no. 18, pp. 1298–1307, 1998.
- J. M. Lindstrom, “Acetylcholine receptors and myasthenia,” Muscle & Nerve, vol. 23, pp. 453–477, 2000.
- P. Taylor, Goodman & Gilman's the Pharmacological Basis of therapeutics, J. G. Hardman, L. E. Limbird, and A. G.Gilman, Eds., 2001.
- J. Guo, M. M. Hurley, J. B. Wright, and G. H. Lushington, “A docking score function for estimating ligand-protein interactions: application to acetylcholinesterase inhibition,” Journal of Medicinal Chemistry, vol. 47, no. 22, pp. 5492–5500, 2004.
- M. Y. Mizutani and A. Itai, “Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors,” Journal of Medicinal Chemistry, vol. 47, no. 20, pp. 4818–4828, 2004.
- J. M. Rollinger, A. Hornick, T. Langer, H. Stuppner, and H. Prast, “Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products,” Journal of Medicinal Chemistry, vol. 47, no. 25, pp. 6248–6254, 2004.
- Glide, Schrödinger, LLC, New York, NY, USA, 2008.
- ROCS 2.3.1, OpenEye Scientific Software, Santa Fe, NM, USA, 2007.
- EON 2.0.1., OpenEye Scientific Software, Santa Fe, NM, USA, 2007.
- N. Huang, B. K. Shoichet, and J. J. Irwin, “Benchmarking sets for molecular docking,” Journal of Medicinal Chemistry, vol. 49, no. 23, pp. 6789–6801, 2006.
- OMEGA 2.3.2, OpenEye Scientific Software, Santa Fe, NM, USA, 2008.
- I. W. Davis, A. Leaver-Fay, V. B. Chen et al., “MolProbity: all-atom contacts and structure validation for proteins and nucleic acids,” Nucleic acids research, vol. 35, pp. W375–W383, 2007.
- V. Sharma, K. K. Pattanaik, V. Jayprakash, A. Basu, and N. Mishra, “A utility script for automating and integrating AutoDock and other associated programs for virtual screening,” Bioinformation, vol. 4, pp. 84–86, 2009.
- S. L. Dixon, A. M. Smondyrev, E. H. Knoll, S. N. Rao, D. E. Shaw, and R. A. Friesner, “PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results,” Journal of Computer-Aided Molecular Design, vol. 20, no. 10-11, pp. 647–671, 2006.
- S. L. Dixon, A. M. Smondyrev, and S. N. Rao, “PHASE: a novel approach to pharmacophore modeling and 3D database searching,” Chemical Biology and Drug Design, vol. 67, no. 5, pp. 370–372, 2006.
- A. Bender and R. C. Glen, “A discussion of measures of enrichment in virtual screening: Comparing the information content of descriptors with increasing levels of sophistication,” Journal of Chemical Information and Modeling, vol. 45, no. 5, pp. 1369–1375, 2005.
- T. Lovell, H. Chen, P. D. Lyne, F. Giordanetto, and J. Li, “Erratum: On evaluating molecular-docking methods for pose prediction and enrichment factors (Journal of Chemical Information and Modeling (2006) 46 (401-415)),” Journal of Chemical Information and Modeling, vol. 48, no. 1, p. 246, 2008.
- A. N. Jain and A. Nicholls, “Recommendations for evaluation of computational methods,” Journal of Computer-Aided Molecular Design, vol. 22, no. 3-4, pp. 133–139, 2008.
- M. Stahl and M. Rarey, “Detailed analysis of scoring functions for virtual screening,” Journal of Medicinal Chemistry, vol. 44, no. 7, pp. 1035–1042, 2001.
- J.-F. Truchon and C. I. Bayly, “Evaluating virtual screening methods: good and bad metrics for the “early recognition” problem,” Journal of Chemical Information and Modeling, vol. 47, no. 2, pp. 488–508, 2007.
- N. Triballeau, F. Acher, I. Brabet, J.-P. Pin, and H.-O. Bertrand, “Virtual screening workflow development guided by the “receiver operating characteristic” curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4,” Journal of Medicinal Chemistry, vol. 48, no. 7, pp. 2534–2547, 2005.
- P. Bar-On, C. B. Millard, M. Harel et al., “Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine,” Biochemistry, vol. 41, no. 11, pp. 3555–3564, 2002.
- G. Kryger, I. Silman, and J. L. Sussman, “Structure of acetylcholinesterase complexed with E2020 (Ariceptρ): implications for the design of new anti-Alzheimer drugs,” Structure, vol. 7, no. 3, pp. 297–307, 1999.
- H. Dvir, H. L. Jiang, D. M. Wong et al., “X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement,” Biochemistry, vol. 41, no. 35, pp. 10810–10818, 2002.
- E. H. Rydberg, B. Brumshtein, H. M. Greenblatt et al., “Complexes of Alkylene-linked tacrine dimers with Torpedo californica acetylcholinesterase: Binding of bis(5)-tacrine produces a dramatic rearrangement in the active-site gorge,” Journal of Medicinal Chemistry, vol. 49, no. 18, pp. 5491–5500, 2006.
- V. Tumiatti, V. Andrisano, R. Banzi et al., “Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 3. Effect of replacing the inner polymethylene chain with cyclic moieties,” Journal of Medicinal Chemistry, vol. 47, no. 26, pp. 6490–6498, 2004.
- C. Melchiorre, V. Andrisano, M. L. Bolognesi et al., “Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease,” Journal of Medicinal Chemistry, vol. 41, no. 22, pp. 4186–4189, 1998.
- G. Lin, G.-H. Chen, and H.-C. Ho, “Conformationally restricted carbamate inhibitors of horse serum butyrylcholinesterase,” Bioorganic and Medicinal Chemistry Letters, vol. 8, no. 19, pp. 2747–2750, 1998.
- B. Tasso, M. Catto, O. Nicolotti et al., “Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease,” European Journal of Medicinal Chemistry, vol. 46, no. 6, pp. 2170–2184, 2011.
- W. Luo, Q.-S. Yu, S. S. Kulkarni et al., “Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine,” Journal of Medicinal Chemistry, vol. 49, no. 7, pp. 2174–2185, 2006.
- L. Savini, G. Campiani, A. Gaeta et al., “Novel and potent tacrine-related hetero- and homobivalent ligands for acetylcholinesterase and butyrylcholinesterase,” Bioorganic and Medicinal Chemistry Letters, vol. 11, no. 13, pp. 1779–1782, 2001.
- S. Bencharit, C. L. Morton, J. L. Hyatt et al., “Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition,” Chemistry and Biology, vol. 10, no. 4, pp. 341–349, 2003.